Skip to main content
Erschienen in: PharmacoEconomics 7/2013

01.07.2013 | Practical Application

Productivity Costs in Economic Evaluations: Past, Present, Future

verfasst von: Marieke Krol, Werner Brouwer, Frans Rutten

Erschienen in: PharmacoEconomics | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Productivity costs occur when the productivity of individuals is affected by illness, treatment, disability or premature death. The objective of this paper was to review past and current developments related to the inclusion, identification, measurement and valuation of productivity costs in economic evaluations. The main debates in the theory and practice of economic evaluations of health technologies described in this review have centred on the questions of whether and how to include productivity costs, especially productivity costs related to paid work. The past few decades have seen important progress in this area. There are important sources of productivity costs other than absenteeism (e.g. presenteeism and multiplier effects in co-workers), but their exact influence on costs remains unclear. Different measurement instruments have been developed over the years, but which instrument provides the most accurate estimates has not been established. Several valuation approaches have been proposed. While empirical research suggests that productivity costs are best included in the cost side of the cost-effectiveness ratio, the jury is still out regarding whether the human capital approach or the friction cost approach is the most appropriate valuation method to do so. Despite the progress and the substantial amount of scientific research, a consensus has not been reached on either the inclusion of productivity costs in economic evaluations or the methods used to produce productivity cost estimates. Such a lack of consensus has likely contributed to ignoring productivity costs in actual economic evaluations and is reflected in variations in national health economic guidelines. Further research is needed to lessen the controversy regarding the estimation of health-related productivity costs. More standardization would increase the comparability and credibility of economic evaluations taking a societal perspective.
Fußnoten
1
This review generally focuses on issues regarding productivity cost estimation in economic evaluations conducted to inform (national) decision makers regarding the relative cost effectiveness of new health interventions. Some of the topics discussed may therefore not fully relate to, for instance, the US healthcare system, where employers are significant purchasers of healthcare.
 
2
Note that the inclusion of productivity costs does not necessarily lower cost-effectiveness estimates or favour interventions for productive individuals [1720].
 
3
Whether it is relevant to include potential effects on future productivity depends on the valuation approach. If the friction cost approach is adopted, these costs normally need not be included, since they will commonly fall beyond the friction period. Their inclusion is important, however, when using the human capital approach.
 
4
Valuation approaches are further discussed in Sect. 5 of this review.
 
5
Obviously, the term productivity costs is less appropriate if lost productivity is valued in terms of effects instead of costs.
 
Literatur
1.
Zurück zum Zitat Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20(1):2–15.PubMedCrossRef Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20(1):2–15.PubMedCrossRef
2.
Zurück zum Zitat Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions (CHE research paper no. 54). New York: Centre for Health Economics; 2010. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions (CHE research paper no. 54). New York: Centre for Health Economics; 2010.
3.
Zurück zum Zitat Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9.PubMedCrossRef Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9.PubMedCrossRef
4.
Zurück zum Zitat Johannesson M, Jönsson B, Jönsson L, Kobelt G, Zethraeus N. Why should economic evaluations of medical innovations have a societal perspective? OHE briefing. 2009;51:1–32. Johannesson M, Jönsson B, Jönsson L, Kobelt G, Zethraeus N. Why should economic evaluations of medical innovations have a societal perspective? OHE briefing. 2009;51:1–32.
5.
Zurück zum Zitat Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–42. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–42.
6.
Zurück zum Zitat Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–37.
7.
Zurück zum Zitat Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. J Health Econ. 2012;31(1):158–68.PubMedCrossRef Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. J Health Econ. 2012;31(1):158–68.PubMedCrossRef
8.
Zurück zum Zitat Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator—a further discussion. Health Econ. 1997;6(5):511–4. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator—a further discussion. Health Econ. 1997;6(5):511–4.
9.
Zurück zum Zitat Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011;72(2):185–92.PubMedCrossRef Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011;72(2):185–92.PubMedCrossRef
10.
11.
Zurück zum Zitat Olsen J, Richardson J. Production gains from health care: what should be included in cost-effectiveness analysis. Soc Sci Med. 1999;49:17–26.PubMedCrossRef Olsen J, Richardson J. Production gains from health care: what should be included in cost-effectiveness analysis. Soc Sci Med. 1999;49:17–26.PubMedCrossRef
12.
Zurück zum Zitat Johannesson M. A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy. 1995;33(1):59–66.PubMedCrossRef Johannesson M. A note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy. 1995;33(1):59–66.PubMedCrossRef
13.
Zurück zum Zitat Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
14.
Zurück zum Zitat Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15.
Zurück zum Zitat Brouwer WBF, Exel JA, Baltussen RMPM, Rutten FFH. A dollar is a dollar-or is it? Value Health. 2006;9(5):341–7.PubMedCrossRef Brouwer WBF, Exel JA, Baltussen RMPM, Rutten FFH. A dollar is a dollar-or is it? Value Health. 2006;9(5):341–7.PubMedCrossRef
16.
Zurück zum Zitat Lindholm L, Lofroth E, Rosen M. Does productivity influence priority setting? A case study from the field of CVD prevention. Cost Eff Resour Alloc. 2008;17(6):6.CrossRef Lindholm L, Lofroth E, Rosen M. Does productivity influence priority setting? A case study from the field of CVD prevention. Cost Eff Resour Alloc. 2008;17(6):6.CrossRef
17.
Zurück zum Zitat Pritchard C, Sculpher M. Productivity costs: principles and practice in economic evaluation. London: Office of Health Economics; 2000. Pritchard C, Sculpher M. Productivity costs: principles and practice in economic evaluation. London: Office of Health Economics; 2000.
18.
Zurück zum Zitat Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ. 1994;3(6):385–93. Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ. 1994;3(6):385–93.
19.
Zurück zum Zitat Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601–19.PubMed Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics. 2011;29(7):601–19.PubMed
21.
Zurück zum Zitat Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW. Presenteeism: critical issues. J Occup Environ Med. 2010;52(11):1055–67.PubMedCrossRef Brooks A, Hagen SE, Sathyanarayanan S, Schultz AB, Edington DW. Presenteeism: critical issues. J Occup Environ Med. 2010;52(11):1055–67.PubMedCrossRef
22.
Zurück zum Zitat Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.PubMedCrossRef Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.PubMedCrossRef
23.
Zurück zum Zitat Brouwer WB, Koopmanschap MA, Rutten FF. Productivity losses without absence: measurement validation and empirical evidence. Health Policy. 1999;48(1):13–27.PubMedCrossRef Brouwer WB, Koopmanschap MA, Rutten FF. Productivity losses without absence: measurement validation and empirical evidence. Health Policy. 1999;48(1):13–27.PubMedCrossRef
24.
Zurück zum Zitat Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 1996;5(1):13–23. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 1996;5(1):13–23.
25.
Zurück zum Zitat Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF. Productivity costs before and after absence from work: as important as common? Health Policy. 2002;61(2):173–187. Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF. Productivity costs before and after absence from work: as important as common? Health Policy. 2002;61(2):173–187.
26.
Zurück zum Zitat Pauly MV, Nicholson S, Xu J, Polsky D, Danzon PM, Murray JF, et al. A general model of the impact of absenteeism on employers and employees. Health Econ. 2002;11(3):221–31.PubMedCrossRef Pauly MV, Nicholson S, Xu J, Polsky D, Danzon PM, Murray JF, et al. A general model of the impact of absenteeism on employers and employees. Health Econ. 2002;11(3):221–31.PubMedCrossRef
27.
Zurück zum Zitat Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML. Measuring the effects of work loss on productivity with team production. Health Econ. 2006;15(2):111–23.PubMedCrossRef Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML. Measuring the effects of work loss on productivity with team production. Health Econ. 2006;15(2):111–23.PubMedCrossRef
28.
Zurück zum Zitat Pauly MV, Nicholson S, Polsky D, Berger ML, Sharda C. Valuing reductions in on-the-job illness: ‘presenteeism’ from managerial and economic perspectives. Health Econ. 2008;17(4):469–85.PubMedCrossRef Pauly MV, Nicholson S, Polsky D, Berger ML, Sharda C. Valuing reductions in on-the-job illness: ‘presenteeism’ from managerial and economic perspectives. Health Econ. 2008;17(4):469–85.PubMedCrossRef
29.
Zurück zum Zitat Severens JL, Laheij RJ, Jansen JB, Van der Lisdonk EH, Verbeek AL. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 1998;12(9):919–23.PubMedCrossRef Severens JL, Laheij RJ, Jansen JB, Van der Lisdonk EH, Verbeek AL. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther. 1998;12(9):919–23.PubMedCrossRef
30.
Zurück zum Zitat Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics. 2005;23(1):47–54.PubMedCrossRef Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics. 2005;23(1):47–54.PubMedCrossRef
31.
Zurück zum Zitat Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics. 2004;22(4):225–44.PubMedCrossRef Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective. Pharmacoeconomics. 2004;22(4):225–44.PubMedCrossRef
32.
Zurück zum Zitat Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care. 2007;13(4):211–7.PubMed Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care. 2007;13(4):211–7.PubMed
33.
Zurück zum Zitat Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–84.PubMedCrossRef Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–84.PubMedCrossRef
34.
Zurück zum Zitat Brouwer WB, Meerding WJ, Lamers LM, Severens JL. The relationship between productivity and health-related QOL: an exploration. Pharmacoeconomics. 2005;23(3):209–18.PubMedCrossRef Brouwer WB, Meerding WJ, Lamers LM, Severens JL. The relationship between productivity and health-related QOL: an exploration. Pharmacoeconomics. 2005;23(3):209–18.PubMedCrossRef
35.
Zurück zum Zitat Lamers LM, Meerding WJ, Severens JL, Brouwer WB. The relationship between productivity and health-related quality of life: an empirical exploration in persons with low back pain. Qual Life Res. 2005;14(3):805–13.PubMedCrossRef Lamers LM, Meerding WJ, Severens JL, Brouwer WB. The relationship between productivity and health-related quality of life: an empirical exploration in persons with low back pain. Qual Life Res. 2005;14(3):805–13.PubMedCrossRef
37.
Zurück zum Zitat Nyman J. Productivity costs revisited: toward a new US policy. Health Econ. 2012;21(12):1387–401.CrossRef Nyman J. Productivity costs revisited: toward a new US policy. Health Econ. 2012;21(12):1387–401.CrossRef
38.
Zurück zum Zitat Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993;4(6):446–54.PubMedCrossRef Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993;4(6):446–54.PubMedCrossRef
39.
Zurück zum Zitat Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ. 1997;6(5):505–10. Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ. 1997;6(5):505–10.
40.
Zurück zum Zitat Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ. 1997;6(3):253–9. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ. 1997;6(3):253–9.
41.
Zurück zum Zitat Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics. 2005;23(5):449–59.PubMedCrossRef Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics. 2005;23(5):449–59.PubMedCrossRef
42.
Zurück zum Zitat Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. Reply to Johanneson’s and Karlsson’s comment. J Health Econ. 1997;16:257–9.CrossRef Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. Reply to Johanneson’s and Karlsson’s comment. J Health Econ. 1997;16:257–9.CrossRef
43.
Zurück zum Zitat Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ. 1997;16(2):249–55 (discussion 257–9). Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ. 1997;16(2):249–55 (discussion 257–9).
44.
Zurück zum Zitat Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics. 2005;23(2):105–11.PubMedCrossRef Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics. 2005;23(2):105–11.PubMedCrossRef
45.
Zurück zum Zitat Meltzer D, Weckerle C, Chang L. Do people consider financial effects in answering quality of life questions? Med Decis Making. 1999;19:517.CrossRef Meltzer D, Weckerle C, Chang L. Do people consider financial effects in answering quality of life questions? Med Decis Making. 1999;19:517.CrossRef
46.
Zurück zum Zitat Myers J, McCabe S, Gohmann S. Quality-of-life assessment when there is a loss of income. Med Decis Making. 2007;27(1):27–33. Myers J, McCabe S, Gohmann S. Quality-of-life assessment when there is a loss of income. Med Decis Making. 2007;27(1):27–33.
47.
Zurück zum Zitat Richardson J, Peacock SJ, Iezzi A. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. Eur J Health Econ. 2009;10(1):103–9.PubMedCrossRef Richardson J, Peacock SJ, Iezzi A. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. Eur J Health Econ. 2009;10(1):103–9.PubMedCrossRef
48.
Zurück zum Zitat Davidson T, Levin LA. Do individuals consider expected income when valuing health states? Int J Technol Assess Health Care. 2008;24(4):488–94.PubMedCrossRef Davidson T, Levin LA. Do individuals consider expected income when valuing health states? Int J Technol Assess Health Care. 2008;24(4):488–94.PubMedCrossRef
49.
Zurück zum Zitat Sendi P, Brouwer WB. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ. 2005;14(6):643–7.PubMedCrossRef Sendi P, Brouwer WB. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations. Health Econ. 2005;14(6):643–7.PubMedCrossRef
50.
Zurück zum Zitat Krol M, Brouwer W, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics. 2006;24(4):401–14.PubMedCrossRef Krol M, Brouwer W, Sendi P. Productivity costs in health-state valuations: does explicit instruction matter? Pharmacoeconomics. 2006;24(4):401–14.PubMedCrossRef
51.
Zurück zum Zitat Krol M, Sendi P, Brouwer W. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises. Value Health. 2009;12(1):172–80.PubMedCrossRef Krol M, Sendi P, Brouwer W. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises. Value Health. 2009;12(1):172–80.PubMedCrossRef
52.
Zurück zum Zitat Brouwer WB, Grootenboer S, Sendi P. The incorporation of income and leisure in health state valuations when the measure is silent: an empirical inquiry into the sound of silence. Med Decis Making. 2009;29(4):503–12. Brouwer WB, Grootenboer S, Sendi P. The incorporation of income and leisure in health state valuations when the measure is silent: an empirical inquiry into the sound of silence. Med Decis Making. 2009;29(4):503–12.
53.
Zurück zum Zitat Brouwer WB, Rutten FF. The missing link: on the line between C and E. Health Econ. 2003;12(8):629–36.PubMedCrossRef Brouwer WB, Rutten FF. The missing link: on the line between C and E. Health Econ. 2003;12(8):629–36.PubMedCrossRef
54.
Zurück zum Zitat Culyer AJ, Bombard Y. An equity framework for health technology assessments. Making: Med Decis.; 2011. Culyer AJ, Bombard Y. An equity framework for health technology assessments. Making: Med Decis.; 2011.
55.
Zurück zum Zitat Brouwer WB, Rutten FF. Health economics: a bridge over troubled water. Eur J Public Health. 2001;11(2):234–6.PubMedCrossRef Brouwer WB, Rutten FF. Health economics: a bridge over troubled water. Eur J Public Health. 2001;11(2):234–6.PubMedCrossRef
56.
Zurück zum Zitat Belgian Health Care Knowledge Centre. Guidelines for pharmacoeconomic evaluations in Belgium (KCE reports 78C). Brussels: KCE; 2008. Belgian Health Care Knowledge Centre. Guidelines for pharmacoeconomic evaluations in Belgium (KCE reports 78C). Brussels: KCE; 2008.
57.
Zurück zum Zitat National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
58.
Zurück zum Zitat Edling A, Stenberg A. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Stockholm: Pharmaceutical Benefits Board; 2003. Edling A, Stenberg A. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Stockholm: Pharmaceutical Benefits Board; 2003.
59.
Zurück zum Zitat College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. Diemen: CVZ; 2006. College voor zorgverzekeringen. Guidelines for pharmacoeconomic research, updated version. Diemen: CVZ; 2006.
60.
Zurück zum Zitat Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2001;35:189–201. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J. 2001;35:189–201.
61.
Zurück zum Zitat Norwegian Medicines Agency. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Norwegian Medicines Agency; 2002. Norwegian Medicines Agency. Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement. Oslo: Norwegian Medicines Agency; 2002.
62.
Zurück zum Zitat Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ. 2005;14(5):435–43.PubMedCrossRef Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ. 2005;14(5):435–43.PubMedCrossRef
63.
Zurück zum Zitat Krol M, Brouwer W, Severens JL, Kaper J, Evers S. Productivity cost calculations: correcting for compensation mechanisms and multiplier effects? Soc Sci Med. 2012;75(11):1981–8.PubMedCrossRef Krol M, Brouwer W, Severens JL, Kaper J, Evers S. Productivity cost calculations: correcting for compensation mechanisms and multiplier effects? Soc Sci Med. 2012;75(11):1981–8.PubMedCrossRef
65.
Zurück zum Zitat Meerding WJ, IJzelenberg W, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol. 2005;58(5):517–23.PubMedCrossRef Meerding WJ, IJzelenberg W, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol. 2005;58(5):517–23.PubMedCrossRef
66.
Zurück zum Zitat Zhang W, Gignac MA, Beaton D, Tang K, Anis AH, Canadian Arthritis Network Work Productivity Group. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol. 2010;37(9):1805–14.PubMedCrossRef Zhang W, Gignac MA, Beaton D, Tang K, Anis AH, Canadian Arthritis Network Work Productivity Group. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol. 2010;37(9):1805–14.PubMedCrossRef
67.
Zurück zum Zitat van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405–15. van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405–15.
68.
Zurück zum Zitat Zhang W, Bansback N, Boonen A, Severens JL, Anis AH. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. Value Health. 2012;15(1):46–54.PubMedCrossRef Zhang W, Bansback N, Boonen A, Severens JL, Anis AH. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. Value Health. 2012;15(1):46–54.PubMedCrossRef
69.
Zurück zum Zitat Reid M. Economics of household production. New York: Wiley; 1934. Reid M. Economics of household production. New York: Wiley; 1934.
70.
Zurück zum Zitat Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses. Variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111–24.PubMedCrossRef Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses. Variations in the literature. Int J Technol Assess Health Care. 2000;16(1):111–24.PubMedCrossRef
71.
Zurück zum Zitat Gerard K. Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy. 1992;21(3):249–79.PubMedCrossRef Gerard K. Cost-utility in practice: a policy maker’s guide to the state of the art. Health Policy. 1992;21(3):249–79.PubMedCrossRef
72.
Zurück zum Zitat Weisbrod BA. The valuation of human capital. J Polit Econ. 1961;69(5):425–36.CrossRef Weisbrod BA. The valuation of human capital. J Polit Econ. 1961;69(5):425–36.CrossRef
73.
Zurück zum Zitat Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–10.PubMedCrossRef Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34(9):1005–10.PubMedCrossRef
74.
Zurück zum Zitat Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.PubMedCrossRef Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.PubMedCrossRef
75.
76.
Zurück zum Zitat Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics. 1997;11(5):385–8.PubMedCrossRef Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics. 1997;11(5):385–8.PubMedCrossRef
77.
Zurück zum Zitat Meltzer D, Johannesson M. Inconsistencies in the “societal perspective” on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making. 1999;19(4):371–7. Meltzer D, Johannesson M. Inconsistencies in the “societal perspective” on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making. 1999;19(4):371–7.
78.
Zurück zum Zitat Tilling C, Krol M, Tsuchiya A, Brazier J, Brouwer W. In or out? Income losses in health state valuations: a review. Value Health. 2010;13(2):298–305. Tilling C, Krol M, Tsuchiya A, Brazier J, Brouwer W. In or out? Income losses in health state valuations: a review. Value Health. 2010;13(2):298–305.
79.
Zurück zum Zitat Waldman JD, Kelly F, Arora S, Smith HL. The shocking cost of turnover in health care. Health Care Manage Rev. 2004;29(1):2–7. Waldman JD, Kelly F, Arora S, Smith HL. The shocking cost of turnover in health care. Health Care Manage Rev. 2004;29(1):2–7.
80.
Zurück zum Zitat Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269–80.PubMedCrossRef Koopmanschap MA, van Exel JN, van den Berg B, Brouwer WB. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26(4):269–80.PubMedCrossRef
81.
Zurück zum Zitat van Exel J, Bobinac A, Koopmanschap M, Brouwer W. The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Rev Pharmacoecon Outcomes Res. 2008;8(6):557–61.PubMedCrossRef van Exel J, Bobinac A, Koopmanschap M, Brouwer W. The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Rev Pharmacoecon Outcomes Res. 2008;8(6):557–61.PubMedCrossRef
82.
Zurück zum Zitat van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835–45.PubMedCrossRef van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835–45.PubMedCrossRef
83.
Zurück zum Zitat van den Berg B, Al M, Brouwer W, van Exel J, Koopmanschap M. Economic valuation of informal care: the conjoint measurement method applied to informal caregiving. Soc Sci Med. 2005;61(6):1342–55.PubMedCrossRef van den Berg B, Al M, Brouwer W, van Exel J, Koopmanschap M. Economic valuation of informal care: the conjoint measurement method applied to informal caregiving. Soc Sci Med. 2005;61(6):1342–55.PubMedCrossRef
84.
Zurück zum Zitat van den Berg B, Brouwer WB, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004;5(1):36–45.PubMedCrossRef van den Berg B, Brouwer WB, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004;5(1):36–45.PubMedCrossRef
85.
Zurück zum Zitat Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF. The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time. Int J Technol Assess Health Care. 1999;15(1):147–60. Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF. The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time. Int J Technol Assess Health Care. 1999;15(1):147–60.
86.
Zurück zum Zitat Grocott R, Metcalfe S, Schoeler R, Priest V, Hall C, Brougham M, et al. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Wellington: PHARMAC Pharmaceutical Management Agency; 2007. Grocott R, Metcalfe S, Schoeler R, Priest V, Hall C, Brougham M, et al. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. Wellington: PHARMAC Pharmaceutical Management Agency; 2007.
Metadaten
Titel
Productivity Costs in Economic Evaluations: Past, Present, Future
verfasst von
Marieke Krol
Werner Brouwer
Frans Rutten
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing AG
Erschienen in
PharmacoEconomics / Ausgabe 7/2013
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0056-3

Weitere Artikel der Ausgabe 7/2013

PharmacoEconomics 7/2013 Zur Ausgabe